skip to main content
Global Search Configuration

About Joseph

Maryland, USA

16+ years of experience

Joe Haas
Joe has covered a wide range of biopharmaceutical stories for the past 11 years and contributes to Pink Sheet, Scrip and related Pharma Intelligence publications. His specialties include business development, commercial strategies and infectious diseases.
Joe began reporting on the pharmaceutical industry upon joining the Pink Sheet in 2007. Key developments he has analyzed include Genzyme’s acquisition by Sanofi; the dynamics of the hepatitis C market from the development of telaprevir and boceprevir through the market’s emergence into a mature therapeutic space; nascent R&D efforts in NASH; and deal-making among pharma, biotechs and academic/research institutions.

Analyst Articles

Articles by Joseph